Business
ADC Therapeutics is a commercial-stage oncology company focused on antibody drug conjugates, led by ZYNLONTA.
ADC Therapeutics grew ZYNLONTA revenue and improved margins, but cash burn worsened and equity stayed negative.
The read at a glance✓ Audited against SEC data
- Business mix — Commercial ADC oncology companyNote
- Revenue — Revenue +14.9% to $81.4MOK
- Profitability — Net loss improved to $142.6MOK
- Cash burn — Free cash flow was -$141.4MWatch
- Balance sheet — Equity remained negativeWatch
- Insiders — 0 buys / 3 sellsWatch
- Accounting — Altman-Z distress; EQ greyWatch
Where the revenue comes from
Fiscal 2025, as ADC Therapeutics SA reports it. History and quarterly detail are in the app.
- Product revenues, net$73.6M
- License revenues and royalties$7.8M
- License revenues$5.0M
- Royalties$2.8M
Latest filings
- 10-Q · Quarterly report2026-08-13
- 8-K · Company announcement2026-08-13
- 8-K · Company announcement2026-07-02
- 8-K · Company announcement2026-06-24
- 8-K · Company announcement2026-06-03
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about ADC Therapeutics SA, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.